All News
Filter News
Found 2,993 articles
-
Response Biomedical Chief Financial Officer and Vice President Finance to Leave
12/17/2008
-
Roche Release: New Data From Largest-Ever Clinical Trials In CLL Show Mabthera Enables Leukaemia Patients To Live Longer Without Their Disease Progressing
12/11/2008
-
Roche Release: Mabthera Maintenance Therapy Helps Non-Hodgkin’s Lymphoma Patients Live For Years Longer Without Their Disease Progressing
12/10/2008
-
Response Biomedical Announces Third Quarter Results
11/13/2008
-
Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference
10/30/2008
-
Applied Biosystems Launches New High-Throughput Genotyping System
10/21/2008
-
Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9/26/2008
-
Recent University of Heidelberg Research Shows Significant Benefits In Acute Ischaemic Stroke With Actilyse(R) Beyond Currently FDA Approved Three Hour Treatment Window
9/25/2008
-
Roche Completes Acquisition of ARIUS Research Inc.
9/24/2008
-
Response Biomedical Announces Second Quarter Results
8/15/2008
-
Roche Release: Landmark Studies to Assess Risk of Exposure to Elevated Levels of EMS
8/4/2008
-
Roche MabThera Filed in the EU for Treatment of Most Common Leukaemia in Adults
7/31/2008
-
Response Biomedical and Roche Diagnostics Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests
7/29/2008
-
Studies Assessed by European Health Authority Conclude that Impurity in Roche's Viracept(R) Did Not Increase Patients' Risk of Cancer
7/25/2008
-
Roche (JOBS) to Buy Canada's ARIUS Research Inc. for C$191 Million
7/23/2008
-
Trimeris, Inc. Reports Second Quarter 2008 FUZEON® Sales Results
7/21/2008
-
Emory University Study: Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
6/3/2008
-
Roche Signs Exclusive Distribution Deal With DxS Ltd For K-RAS And EGFR Cancer Mutation Tests; Tests Identify Genetic Mutations That Can Affect Patient Response To Certain Cancer Drugs
6/2/2008
-
Genentech, Inc., Biogen Idec, Inc. (Massachusetts) Says Phase II/III Study Of Rituxan Fails To Meet Endpoints
4/29/2008
-
Trimeris, Inc. Reports First Quarter 2008 FUZEON(R) Sales Results
4/17/2008